Great post Mozz.
Just on this part about Dimerix's deals, I have come to the slow realisation that we are still far earlier in the story than many investors think we are, or would like us to be. I've been very guilty of this front-running myself recently, and I think it took me getting in to see the PAR team at work, and get a true grasp on the scope of work they are undertaking, to realise that I have put a regional deal way up on a pedestal and forefronted it's importance over all other progress being made. I'm not here to convince anyone else what to think, I can totally understand how you can easily get swept up thinking the wheels are wobbly on PAR because of no deals yet (and without doubt much of the blame for this is on Paul for talking-up the proximity of deals and other non-dilutive funding for so many fruitless years). I'd begun to convince myself that things were going pear-shaped. However, I think I have reset my mindset again for the next haul towards Interim Analysis. If they can secure the funding for that, even if it's inevitably dilutionary, I think the SP might be well-supported even if deals only come later. If they can secure the finances on whatever the best terms possible to reach that IA milestone, keep on track with 50% dosed by end of 2025 setting an IA readout for July 2026 or thereabouts as planned, then we are progressing down main street - and everything else should come in it's own good time. A regional deal appears to be a major part of their 2025 plans, and may be required to get LO's into the money, so I wish them well with getting that done. However, I also now believe that a trial funded to IA, and 50%-dosed by end of December might be more supportive to the SP than people realise.....and i'm making a conscious decision to put deals aside in my mind for now, and focus on what their plans are for funding until IA, and then get a solid look at this webinar and Zilosuls chances of success at IA. It's taken me a while to realise it, but this is the real show for the next 12 months, over and above deals.
for a while. Bio's are definitely full of lots of ups and downs and having read a few war stories, there is never a straight line. Unfortunately the Australian Bio market is not well supported compared to the US hence our share prices a generally a way off their counterparts at the same stages.
(20min delay)